Lucid Diagnostics Inc
Research Lucid Diagnostics Inc (LUCD) on Bullrun: market cap USD 192.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLUCD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 192.66M
- Financial periodQ1 2026
- RevenueUSD 1.26M
- Net income-USD 13.91M
- Free cash flow-USD 12.32M
- Gross margin-29.4%
Valuation Snapshot
latest market cap is USD 192.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.71M | -USD 58.01M | -USD 46.68M | -41.7% | -0.8 | USD 34.71M | USD 25.82M | USD 10.94M |
| FY2024 | USD 4.35M | -USD 45.53M | -USD 44.44M | -63.3% | -1.05 | USD 22.36M | USD 21.25M | USD 5.39M |
| FY2023 | USD 2.43M | -USD 52.67M | -USD 33.04M | n/a | -1.26 | USD 18.90M | USD 15.26M | -USD 2.31M |
| FY2022 | USD 377.00K | -USD 56.17M | -USD 32.89M | 100.0% | -1.55 | USD 22.47M | USD 2.08M | USD 23.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 192.66M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 142.90M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 51.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 60.46M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 53.19M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 187.51M | n/a | n/a | n/a |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lucid Diagnostics Inc's market cap?
Lucid Diagnostics Inc's market capitalization is USD 192.66M.
What does Lucid Diagnostics Inc do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.